15-12G - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

EFFECT - Quotient Ltd (0001596946) (Filer)

POS AM - Quotient Ltd (0001596946) (Filer)

JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effect no earlier than ten days after the date of that Form 25 filing. The Company expects that as a result of this voluntary delisting, the last trading day of its ordinary shares on the Nasda

JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market. The new CUSIP

JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when the market opens on November 3, 2022 on the Nasdaq under the existing symbol "QTNT." The Reverse Stock Split is primarily intended to bring the Company into compliance

Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

The World Economic Forum's New Champions Community brings together purpose driven companies of mid-size whose leadership is mindful of their impact on society and aspiring in building a better future​These companies champion new business models and technologies to build resilience into their businesses, industries and communities JERSEY, Channel Islands, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced it was selected by the World Economic Forum to join their New Champions Community. "We are delighted to welcome Quotient Limited as part of the New Champions Community

• The National Screening Laboratory of Sanquin Blood Supply Foundation joins MosaiQ Innovator's Circle JERSEY, Channel Islands, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices (Sanquin), headquartered in Amsterdam, the Netherlands has joined MosaiQ Innovator's Circle. Sanquin Blood Supply is responsible for safe and efficient blood supply in the Netherlands. The MosaiQ Innovator's Circle is a community of experts, representing laboratories from nations around the w

MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica

JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot

JERSEY, Channel Islands, July 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient's MosaiQ solution. Under the collaboration agreement, InfYnity Biomarkers will assist Quotient in the research and design of infectious disease assays to enrich and expand the MosaiQ Serology Disease Screening (SDS) menu and reduce time and cost of development and commer

JERSEY, Channel Islands, July 01, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the scheduled grant of equity awards to Mr. Steven Zuiderwijk, who has been appointed as the Chief Strategy & Business Development Officer of the Company effective July 1, 2022. In connection with his appointment, the Company granted Mr. Zuiderwijk 112,780 performance-based restricted share units (PSUs) (the Sign-On PSUs), 67,668 Restricted Share Units (RSUs) (the Sign-On RSUs) and share options to purchase 45,112 of the Company's ordinary shares (the Sign-On Options). Such grants were issued outside of the Company's 2014 Stock In

Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously

Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00

MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica

JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot

Financial Position Amended Secured Notes: Reduces the company's cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022  MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (IH) donor tenders; 20 European IH donor tender submissions expected in the next 18 monthsDistribution Network: 9 international agreements in place and expanding global distribution ne

Pre-announces FY 2022 revenue of $38.5 millionSecured $1.4 million of orders in Q1 FY23 for recently CE Marked Extended IH MosaiQ Solution$83.2 million in cash and investments as of March 31, 2022 JERSEY, Channel Islands, June 21, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it is rescheduling the release of its financial results for the fourth quarter and full year 2022 ended March 31, 2022. The Company will release these financial results and host a conference call before market open on Friday, June 24, 2022. Quotient expects to report reagent business generated product sales of $9.8 million in the fourth quarter

JERSEY, Channel Islands, June 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2022 will be released before market open on Wednesday, June 22, 2022. Title:Quotient Fourth Quarter and Full Year 2021 Financial Results and Conference Call  Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial Officer  Date:Wednesday, June 22, 2022Time:8:00am ET/ 14:00 CET  Conference CallDial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13729874  Webcast:We

MosaiQ™ Solution: Transfusion Diagnostics: The Notified Body completed the assessment of the Company's technical dossier and has advised that it will recommend the MosaiQ Expanded Immunohematology (IH) microarray for CE marking approval;Commercial Execution: In anticipation of CE marking, the Company's Commercial team is preparing to submit more than 20 tender responses within the EU over the next 18-24 months; At the same time, the Company is actively pursuing distribution partnerships in the EU, Middle East and Africa;Manufacturing & Operations: Scale up in progress to support the anticipated MosaiQ commercial launch; Finalized decision on second manufacturing line to meet targeted market

JERSEY, Channel Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2021 will be released before market open on Tuesday, February 8, 2022. Quotient will host a conference call to discuss its third quarter financial results at 8:00am Eastern Time the same day. Participants may access the conference call by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International), using conference ID 13725727. The conference call will be webcast live on the Company's website at www.quotientbd.com. A replay of the conference call will be available through

Alba by Quotient: Revenues exceeded guidance; Achieved year-over year growth in Q2 FY 2022 of 15.9%Financial Position: Available cash & short-term investments of $141.8 millionBusiness Update: Communication issued on November 9, 2021; providing a progress update on development and upcoming commercialization JERSEY, Channel Islands, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its financial results for the second quarter of fiscal year 2022 and filed the quarterly report on Form 10-Q. Alba by Quotient – Revenues exceeded guidance and continued to driv

Executive Leadership Team: Recent new hires will support anticipated rapid growth and help lead future development MosaiQ™ Solution Transfusion Dx: The Expanded Immunohematology CE regulatory dossier has been submitted with 20 specificities; and Expanded Serological Disease Screening immunoassay microarray is progressing towards field trials expected to begin in Q2 CY 2022Commercial Execution: Six MosaiQ tender evaluations are in progress; Multiple distributors identified with more than 100 qualified customer targets Potential New Market Segments: Initiated an R&D program to develop Clinical Diagnostic solutions, focusing first on potential candidates for the $2B Allergy IVD market. Quotie

JERSEY, Channel Islands, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that financial results for its fiscal second quarter ended September 30, 2021 will be released before market open on Tuesday, November 9, 2021. Quotient will host a conference call to discuss its second quarter financial results at 8:00 a.m. Eastern Time the same day. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13724411. The conference call will be webcast live on the Company's website at www.quotientbd.com. A replay of this conference call will be a

3 - Quotient Ltd (0001596946) (Issuer)

3 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

4 - Quotient Ltd (0001596946) (Issuer)

Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.

JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Mé

JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil

JERSEY, Channel Islands, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Dr. Christine Ginocchio as Chief Scientific & Medical Officer (CSMO). "We are delighted to welcome Dr. Ginocchio in this important new role as we prepare for the launch of our MosaiQ solution. Christine's 40 years' experience in clinical diagnostics, laboratory management, and medical education, brings significant added value to Quotient. Dr. Ginocchio will be instrumental in setting the strategic direction for all scientific and medical activities and will support us in leveraging our extensive experience in diagnostics. Chr

Gainers Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering. Palisade Bio, Inc. (NASDAQ:PALI) shares jumped 80.1% to $5.80. Palisade Bio announced $2.5 million registered direct offering and concurrent private placement priced above market under Nasdaq rules. Silo Pharma, Inc. (NASDAQ:SILO) gained 63.7% to $5.60 after the company announced study results of SPU-21 for arthritis. The company said SPU-21 is effective in controlling arthritis progression. F-star Therapeutics, Inc. (NASDAQ:FSTX) shares gained 42.8% to $5.84. F-Star Th

Gainers Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares rose 105% to $0.41 in pre-market trading after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering. Evaxion Biotech A/S (NASDAQ:EVAX) rose 34.4% to $2.38 in pre-market trading. Evaxion Biotech said on Dec 22, the FDA notified the company that it had reviewed the company's IND for Phase 2b clinical trial of EVX-01 in combination with Keytruda. Sesen Bio, Inc. (NASDAQ:SESN) shares rose 30.4% to $0.6590 in pre-market trading after the company and Carisma Therapeutics announced an increased special dividend of $70 million, or $0.34 per share, in connect

Gainers Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ:QTNT) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ:BXRX) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ:PALI) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction i

Gainers Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 143.4% to $10.71 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 20.7 million shares, making up 17470.8% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million. Quotient (NASDAQ:QTNT) shares increased by 93.95% to $0.45. Trading volume for Quotient's stock is 38.6 million as of 12:30 EST. This is 4861.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 million. Palisade Bio (NASDAQ:PALI) shares moved upwards by 53.59% to $2.78. The current volume of 6.2 million shares is 466.2% of Palisade

Gainers Quotient (NASDAQ:QTNT) stock moved upwards by 114.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million. Baudax Bio (NASDAQ:BXRX) shares increased by 84.34% to $4.24. The market value of their outstanding shares is at $2.3 million. Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 49.19% to $18.62. The market value of their outstanding shares is at $29.7 million. TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 27.85% to $0.78. The company's market cap stands at $10.1 million. Journey Medical (NASDAQ:DERM) shares increased by 20.33% to $1.42. The company's market cap stands at $25.1 million. Nuwellis (N

Gainers Quotient Limited (NASDAQ:QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Esports Entertainment Group, Inc. (NASDAQ:GMBL) rose 62.2% to $0.1281 in pre-market trading after declining over 10% on Wednesday. Esports Entertainment Group recently named Alex Igelman as Chief Executive Officer. Baudax Bio, Inc. (NASDAQ:BXRX) shares rose 37.4% to $3.16 in pre-market trading after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. AEye, Inc. (NASDAQ:LIDR

Gainers Quotient (NASDAQ:QTNT) stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 143.5% of its average volume over the last 100 days. The company's market cap stands at $1.1 million. Baudax Bio (NASDAQ:BXRX) shares moved upwards by 14.34% to $2.63. The market value of their outstanding shares is at $1.4 million. OncoCyte (NASDAQ:OCX) stock increased by 12.66% to $0.34. The market value of their outstanding shares is at $40.1 million. Lucira Health (NASDAQ:LHDX) shares moved upwards by 12.0% to $0.14. The company's market cap stands at $5.6 million. Sharecare (NASDAQ:SHCR) stock rose 11.46% to $

Gainers Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect. Minerva Surgical, Inc. (NASDAQ:UTRS) shares jumped 90.1% to $0.3089 after the company reported a $30 million private placement of common stock led by Accelmed Partners. Jounce Therapeutics, Inc. (NASDAQ:JNCE) climbed 61.3% to $1.19 after Gilead Sciences announced plans to acquire all remaining rights to the company's Immunotherapy GS-1811, an anti-CCR8 antibody, for $67 million. Gorilla Technology Group Inc. (NASDAQ:GRRR) rose 51% to $6.80 after the company announced it i

Gainers Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 314.3% to $16.24 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 35.1 million, which is 16849.9% of its average full-day volume over the last 100 days. The company's market cap stands at $24.6 million. Minerva Surgical (NASDAQ:UTRS) shares moved upwards by 74.83% to $0.28. As of 12:30 EST, Minerva Surgical's stock is trading at a volume of 23.2 million, which is 9788.1% of its average full-day volume over the last 100 days. The company's market cap stands at $8.2 million. Jounce Therapeutics (NASDAQ:JNCE) stock increased by 39.67% to $1.03. The current volume of 30.7 million shares i

Gainers Minerva Surgical (NASDAQ:UTRS) shares increased by 111.6% to $0.34 during Wednesday's pre-market session. The company's market cap stands at $9.9 million. Jounce Therapeutics (NASDAQ:JNCE) shares rose 73.58% to $1.28. The market value of their outstanding shares is at $66.1 million. Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 55.61% to $6.1. The market value of their outstanding shares is at $9.2 million. Alzamend Neuro (NASDAQ:ALZN) stock rose 21.68% to $0.73. The market value of their outstanding shares is at $70.1 million. Journey Medical (NASDAQ:DERM) stock rose 17.25% to $1.36. The market value of their outstanding shares is at $24.0 million. NexImmune (NASD